Researchers at the Translational Genomics Research Institute (TGen), part of City of Hope, have made a significant breakthrough in understanding how multiple neurodegenerative pathologies develop simultaneously in aging brains. Using advanced transgenic mouse models, the team demonstrated that amyloid-beta plaques may act as a primary disease initiator, triggering a cascade of tau and alpha-synuclein accumulation. This finding challenges the longstanding assumption that Alzheimer’s disease, Parkinson’s disease, and related conditions develop through independent mechanisms. The discovery suggests that protein pathologies may interact sequentially rather than in parallel, opening new avenues for therapeutic intervention. By understanding these protein interactions, researchers can now design treatment strategies that target the initiating pathology to prevent downstream accumulation of secondary proteins. This cascade model has profound implications for developing preventive and disease-modifying therapies for the mixed-pathology neurodegeneration commonly observed in older adults.
Was this article helpful?
